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S U M M A R Y
A case of severe endocarditis, with complications of multiple infarction, meningitis, and ruptured mitral
chordae tendineae, caused by Streptococcus agalactiae in a healthy man, is reported. Emergency
cardiovascular surgery was performed on the day of admission. Infective endocarditis caused by S.
agalactiae is very rare, particularly in a healthy adult. In addition, microbiological analysis revealed that
S. agalactiae of sequence type (ST) 19, which belongs to serotype III, was present in the patient’s
vegetation, mitral valve, and blood culture. It was therefore concluded that the endocarditis was caused
by ST19, which has been reported as a non-invasive type of S. agalactiae. This was an extremely rare case
in which S. agalactiae of ST19 caused very severe endocarditis in an adult patient with no underlying
disease.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus agalactiae is a Gram-positive coccus that is known
to cause serious diseases in newborns and pregnant women.
However, an increasing number of cases of S. agalactiae causing
invasive disease in non-pregnant adults have been reported.1 S.
agalactiae infections are thought to occur in individuals with a
chronic underlying disease, such as cancer, diabetes mellitus,
cirrhosis of the liver, or HIV infection. S. agalactiae tends to cause
bacteremia without a focus, as well as skin and soft tissue
infections, particularly in non-pregnant adults. It less frequently
causes meningitis and endocarditis, but the morbidity and
mortality rates of these infections are thought to be high.2 A case
of severe endocarditis caused by S. agalactiae in a healthy man with
no underlying disease is reported here.
2. Case report
A 43-year-old, previously healthy man was admitted to the
hospital with a 2-week history of recurrent episodes of headache
and back pain. The patient had no underlying disease, no history of* Corresponding author. Tel.: +81 3 3342 6111; fax: +81 3 5339-3817.
E-mail address: task300@tokyo-med.ac.jp (I. Nakamura).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).dental visits, no history of use of steroids or immunosuppressive
drugs, and was not an intravenous drug user. On admission, the
patient had disturbance of consciousness, a fever (37.8 8C), and
neck pain, and showed a positive Kernig sign. Laboratory ﬁndings
included a high C-reactive protein (CRP) concentration (30.6 mg/
dl; normal value <0.3 mg/dl) and white blood cell (WBC) count
(16.4  109/l). Several blood cultures were performed. Cerebro-
spinal ﬂuid examination revealed an increase in the number of
cells and a decrease in the level of glucose, which suggested
meningitis.
However, computed tomography (CT) revealed multiple
infarcts throughout the cerebrum, kidney, and spleen and
suggested septic emboli. Neurologists suspected infective endo-
carditis, and echocardiography revealed a vegetation
(13  11 mm) on the mitral valve. Emergency cardiovascular
surgery was performed on the day of admission, which conﬁrmed
the vegetation on the mitral valve and a ruptured mitral chordae
tendineae.
All six blood cultures were positive for S. agalactiae. S. agalactiae
was also isolated from a culture of the mitral valve, which was
removed from the heart. S. agalactiae was also isolated from
cultures of the rectal swab, throat swab, and urine sample taken on
admission.
The patient was initially treated with a combination of
ceftriaxone and gentamicin. Vancomycin was also administeredciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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1 mg/kg) was used on the ﬁrst 14 days, which resulted in an
increase in the patient’s creatinine level from 0.63 mg/dl to
1.09 mg/dl; however, this administration was terminated due to a
worsening of renal function. Ceftriaxone was also administered
during the ﬁrst 6 days (4.0 g/day) and was changed to penicillin G
(24 million units/day) due to impaired liver function. Penicillin G
was changed to ceftriaxone (2.0 g/day) on day 26 of antibiotic
treatment due to an elevation in creatinine level. A follow-up CT
scan was performed 6 weeks later, in which the multiple infarcts
throughout the cerebrum, kidneys, and spleen remained un-
changed. Further blood cultures turned to negative on day 6 of
antibiotic treatment. The patient’s WBC count and CRP levels
decreased to 4.4  109/l and 0.5 mg/dl, respectively, at the end of
the 6 weeks of antibiotic therapy, and the patient was afebrile,
which suggested that the endocarditis had been treated success-
fully.
S. agalactiae strains from the vegetation, mitral valve, blood
culture, and rectal swab were analyzed to determine their
serotype. Serotyping based on the latex agglutination method
was performed in accordance with the instructions provided with
the Strep-B-Latex kit (Denka Seiken Co., Ltd, Tokyo, Japan).
Antimicrobial susceptibility and minimum inhibitory concentra-
tions (MICs) were determined using the MicroScan Walk Away
Plus system (Siemens, Tokyo, Japan) using the broth microdilution
method, in accordance with the guidelines published by the
Clinical and Laboratory Standards Institute in 2012.3
The bacterial isolate from the rectal swab of the patient was
found to be serotype Ia, and those from the vegetation, mitral
valve, throat sample, and blood culture samples were serotype III
(urine was not analyzed). Multilocus sequence typing (MLST), an
unambiguous procedure for characterizing bacterial isolates, was
also performed. Seven housekeeping genes (adhP, pheS, atr, glnA,
sdhA, glcK, and tkt) were ampliﬁed by PCR using oligonucleotide
primers, as reported by Jones et al.4 The ampliﬁcation products
were sequenced directly using ﬂuorescently labeled Applied
Biosystems Big Dye Terminators V3.1 and an Applied Biosystems
3500xL automated sequencer. The serotype Ia strain was found to
be ST23, and all serotype III strains were found to be ST19. The
MICs of these strains are shown in Table 1.
3. Discussion
S. agalactiae is a Gram-positive coccus that can cause serious
invasive diseases in newborns. S. agalactiae also often causes
infections in non-pregnant adult patients with chronic immuno-
suppressive disease, such as cancer, diabetes mellitus, cirrhosis of
the liver, and HIV infection. However, S. agalactiae infection
seldom occurs in non-pregnant adults without predisposingTable 1
Minimum inhibitory concentrations of each antimicrobial agent and their
interpretation against the Streptococcus agalactiae strains isolated from the patient
Antimicrobial agent MIC (mg/l) Interpretationa
PCG <0.03 S
ABPC/SBT <0.25 S
CTRX <0.12 S
EM <0.12 S
CLDM <0.12 S
VCM 0.5 S
LVFX 0.5 S
MIC, minimum inhibitory concentration; PCG, penicillin G; ABPC/SBT, ampicillin/
sulbactam; CTRX, ceftriaxone; EM, erythromycin; CLDM, clindamycin; VCM,
vancomycin; LVFX, levoﬂoxacin; S, sensitive; R, resistant.
a Interpretation (sensitive, intermediate, or resistant) was based on the Clinical
and Laboratory Standards Institute criteria.3conditions.1 The patient in this case report did not have any
apparent predisposing factors for either S. agalactiae infection or
endocarditis.
Previous studies have reported that 2–18% of patients infected
with S. agalactiae are infected in the heart. However, the mortality
rate of S. agalactiae endocarditis is reported to be as high as 40%,
suggesting that valve infections caused by S. agalactiae are more
virulent than those caused by most other streptococcal species.5
Although the frequency of occurrence of complications in patients
with endocarditis (such as infarctions and meningitis) is unknown,
the patient presented here had multiple infarcts and destruction of
the mitral valves, and was hence considered to be a severe case.
There are several serotypes of S. agalactiae, and the pathogenesis
of S. agalactiae infection is believed to be determined by its serotype.
One report comparing the serotype frequency in infants and adults
found a predominance of serotype III and serotype Ia in infant
infections, with a lower frequency of serotypes II and V. The strains
isolated from the present patient were identiﬁed as type III and type
Ia, which have been reported to cause invasive infections in non-
pregnant adult patients.6 Serotype III mainly causes invasive
infections in neonates. Whether there is an association between
the virulence of the serotypes and speciﬁc underlying conditions
remains unclear.7 It has previously been reported that most
serotype III S. agalactiae are of ST17 and ST19, as determined by
MLST. Although ST17 has been reported to cause invasive infections
in neonates, ST19 has been associated with colonization.6
MLST showed that the S. agalactiae cultured from the case
patient’s vegetation, mitral valve, and blood culture samples were
all ST19. In the present case, S. agalactiae of serotype III and ST19
was concluded to be the cause of endocarditis. This was an
extremely rare case in which S. agalactiae of ST19 caused very
severe endocarditis in an adult patient with no underlying disease.
On the other hand, invasive infection in non-pregnant adults
possibly of ST19 has been reported recently.5 The virulence of S.
agalactiae remains unclear, and hence research to further clarify
the pathogenicity of S. agalactiae should be performed in the future.
Endocarditis caused by S. agalactiae is treated based on
regimens for endocarditis caused by viridans streptococci and
Streptococcus bovis, such as a combination of gentamicin with
penicillin G or cephalosporin for the ﬁrst 2 weeks of a 4- to 6-week
course of therapy using penicillin G or cephalosporin. The patient
presented here was treated with ceftriaxone (changed to penicillin
G for part of the treatment) and gentamicin, which resulted in a
favorable outcome. However, the effectiveness of combination
therapy of beta-lactams with gentamicin against endocarditis due
to S. agalactiae remains unclear, and further studies should be
performed in the future.
This was a case of serious endocarditis in an adult man with no
underlying disease. Two types of S. agalactiae (serotype III/ST19
and serotype Ia/ST23) were isolated from the patient. Serotype III/
ST19 was isolated from the patient’s vegetation, mitral valve, and
blood sample and was concluded to be the cause of the
endocarditis.
Although the patient’s endocarditis represented a serious
condition, the patient was treated with the appropriate antibiotics
and immediate surgery, and he recovered with no sequelae.
Research to further clarify the pathogenicity of S. agalactiae should
be performed in the future.
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